Solid Growth Derived from Successful Product Launches and Registrations - Research Report on Volcano, Dr. Reddy's, USANA,

  Solid Growth Derived from Successful Product Launches and Registrations -
    Research Report on Volcano, Dr. Reddy's, USANA, Repligen, and Portola

PR Newswire

NEW YORK, November 13, 2013

NEW YORK, November 13, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Volcano
Corporation (NASDAQ: VOLC), Dr. Reddy's Laboratories Limited (NYSE: RDY),
USANA Health Sciences, Inc. (NYSE: USNA), Repligen Corporation (NASDAQ: RGEN),
and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Volcano Corporation Research Report

On November 4, 2013, Volcano Corporation (Volcano) reported Q3 2013 financial
results. In Q3 2013, the Company generated revenues of $95.8 million, up 2.3%
YoY. Q3 2013 net loss was $8.5 million, or $0.15 per diluted share, compared
with net income of $2.0 million, or $0.04 per diluted share, in Q3 2012.
"Overall, our business experienced solid growth. Growth drivers included a
seven percent increase in our U.S. IVUS revenues, due in great part to a
roughly 30 percent increase in peripheral revenues versus the third quarter a
year ago, as well as a 27 percent increase in combined revenues in Europe,"
said Scott Huennekens, President and CEO of Volcano. The Full Research Report
on Volcano Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/14bf_VOLC]

--

Dr. Reddy's Laboratories Limited Research Report

On October 31, 2013, Dr. Reddy's Laboratories Limited (Dr. Reddy's) reported
unaudited consolidated Q2 FY 2014 financial results (period ended September
30, 2013). In Q2 FY 2014, the Company achieved consolidated revenues of $537
million, up 16.7% YoY. Q2 FY 2014 EBITDA was $152 million, compared with $119
million in Q2 FY 2013. During Q2 FY 2014, Dr. Reddy's launched 19 new generic
products, filed 13 new product registrations, and filed 8 DMFs (Drug Master
Files) globally. The Full Research Report on Dr. Reddy's Laboratories Limited
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/ea85_RDY]

--

USANA Health Sciences, Inc. Research Report

On November 4, 2013, USANA Health Sciences, Inc. (USANA) announced that it is
building a state-of-the-art facility in Beijing, China, worth approximately
$40 million. The Company informed that the new structure will be home to
world-class manufacturing and production operations, and will be the largest
in all of USANA's 19 international markets. The Company expects the
construction of the facility to begin in 2014 and to be operational in late
2015. The Full Research Report on USANA Health Sciences, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/ee40_USNA]

--

Repligen Corporation

On November 7, 2013, Repligen Corporation (Repligen) reported Q3 2013
financial results. On Q3 2013, the Company's total revenue was up 24.6% YoY to
$18.8 million. Q3 2013 net income was $5.9 million, or $0.18 per diluted
share, compared with $1.8 million, or $0.06 per diluted share, in Q3 2012.
Repligen also updated its financial guidance and now expects full-year 2013
total revenue of $67 million to $68 million, compared with the previous
guidance of $65 million to $67 million. The Company confirmed that the
increase in expected total revenues is due to the receipt of royalties from
Bristol-Myers Squibb on its US sales of Orencia, which Repligen will no longer
receive on sales made after December 31, 2013. Additionally, full-year 2013
net income is expected to be $16 million to $18 million. The Full Research
Report on Repligen Corporation - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/fdda_RGEN]

--

Portola Pharmaceuticals, Inc. Research Report

On November 5, 2013, Portola Pharmaceuticals, Inc. (Portola) reported Q3 2013
financial results. In Q3 2013, the Company generated collaboration and license
revenues of $2.8 million, up 274.8% YoY. Q3 2013 net loss attributable to
common stockholders was $18.6 million, or $0.53 per diluted share, compared
with $11.5 million, or $8.38 per diluted share, in Q3 2012. "We believe we
have an exciting portfolio of wholly-owned product candidates. Our lead agent,
betrixaban, is being developed as an anticoagulant for the prevention of fatal
blood clots in acute medically ill patients. Andexanet alfa has the potential
to be a first-in-class reversal agent for anticoagulated patients experiencing
a fatal bleed or requiring emergency surgery. And PRT2070 is a unique oral
dual kinase inhibitor being evaluated in patients with hematologic cancers,
including those with genetically-defined and difficult-to-treat subtypes. With
the proceeds from our recently completed follow-on equity offering, we are
well positioned to advance these assets to value-creating milestones planned
for 2014 and 2015, including Phase 3 APEX data for betrixaban, Biologics
License Application filing for andexanet alfa, and proof-of-concept data for
PRT2070," said William Lis, CEO of Portola. The Full Research Report on
Portola Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/102f_PTLA]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.